Merck (MRK) Interest Expenses (2009 - 2026)
Merck (MRK) posted quarterly Interest Expenses of $479.0 million for Q1 2026, up 53.04% year-over-year from $313.0 million in Q1 2025, and up 16.55% quarter-over-quarter from $411.0 million in Q4 2025.
Merck (MRK) Interest Expenses (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Interest Expenses for 18 consecutive years, with $479.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 53.04% year-over-year to $479.0 million; the TTM figure through Mar 2026 stood at $1.5 billion (up 16.18% YoY), while the FY2025 annual figure was $1.4 billion, up 4.38% from the prior year.
- Interest Expenses climbed to $479.0 million in Q1 2026 per MRK's latest filing, from $411.0 million in the prior quarter.
- Across five years, Interest Expenses topped out at $479.0 million in Q1 2026 and bottomed at $235.0 million in Q4 2022.
- Historically, Interest Expenses has averaged $308.4 million across 5 years, with a median of $310.0 million in 2023.
- Annual changes were most pronounced in 2022 — Interest Expenses slumped 33.88% — and 2026, when it jumped 53.04%.
- Merck's Interest Expenses stood at $235.0 million in 2022, then soared by 31.91% to $310.0 million in 2023, then increased by 15.16% to $357.0 million in 2024, then advanced by 15.13% to $411.0 million in 2025, then climbed by 16.55% to $479.0 million in 2026.
- Business Quant data shows MRK's Interest Expenses at $479.0 million in Q1 2026, $411.0 million in Q4 2025, and $327.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 281.00 Mn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | - |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 462.00 Mn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 435.00 Mn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 673.00 Mn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 247.00 Mn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -244.19 Mn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -333.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 525.00 Mn |
| Jun 30, 2026 | 525.00 Mn |
| Mar 31, 2026 | 479.00 Mn |
| Mar 31, 2026 | 479.00 Mn |
| Dec 31, 2025 | 411.00 Mn |
| Dec 31, 2025 | 411.00 Mn |
| Sep 30, 2025 | 327.00 Mn |
| Sep 30, 2025 | 327.00 Mn |
| Jun 30, 2025 | 305.00 Mn |
| Jun 30, 2025 | 305.00 Mn |
| Mar 31, 2025 | 313.00 Mn |
| Mar 31, 2025 | 313.00 Mn |
| Dec 31, 2024 | 357.00 Mn |
| Dec 31, 2024 | 357.00 Mn |
| Sep 30, 2024 | 330.00 Mn |
| Sep 30, 2024 | 330.00 Mn |
| Jun 30, 2024 | 310.00 Mn |
| Jun 30, 2024 | 310.00 Mn |
| Mar 31, 2024 | 303.00 Mn |
| Mar 31, 2024 | 303.00 Mn |